Side-by-side comparison of AI visibility scores, market position, and capabilities
Houston biotech with visual AI TIMING platform analyzing individual cell behaviors in nanowell grids; $5.78M raised plus NIH STTR grant targeting CAR-T quality release and drug discovery screening.
CellChorus is a Houston-based biotechnology company developing the TIMING (Time-lapse Imaging Microscopy in Nanowell Grids) platform — a visual AI system that analyzes individual cell behaviors over time in nanoscale grid arrays to characterize how cells interact, move, and function, enabling drug developers and cell therapy manufacturers to optimize their biologics and cell therapies with unprecedented single-cell resolution. Founded in 2021 and backed with $5.78 million in equity funding plus $3.4 million in non-dilutive grants including a $2.5 million NIH STTR Fast-Track grant in partnership with University of Houston, CellChorus serves biotech researchers, cell therapy manufacturers, and pharmaceutical companies.
Dominant browser-based collaborative UI design platform at ~$600M ARR and $12.5B valuation; Adobe's $20B acquisition blocked by regulators in 2023, Figma remains independent competing with Sketch and Adobe.
Figma is a San Francisco-based collaborative web-based product design platform that has become the dominant tool for UI/UX designers and product teams — enabling real-time multi-user collaboration on interface design, prototyping, and design system management directly in the browser without installing desktop software. Founded in 2012 by Dylan Field and Evan Wallace and backed by Sequoia, Greylock, and Andreessen Horowitz with over $330 million raised, Figma generated approximately $600 million in ARR in 2023, serving 4 million+ designers and product teams at companies including Microsoft, Airbnb, Twitter, and Uber. Adobe announced a $20 billion acquisition offer in 2022, which was blocked by regulators in 2023 — Figma remains independent.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.